Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake

Kimiz‐Gebologlu, Ilgin; Öncel, Suphi Ş.

doi:10.1016/j.jconrel.2022.05.027

Cited by 178 publications

(86 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A second limitation is that exosome yield was extremely low, and therefore, exosome production efficiency must be increased. At present, many methods for large-scale production of exosomes were available [ 43 ]. These may be worth exploring.…”

Section: Discussionmentioning

confidence: 99%

Human Amniotic Fluid Mesenchymal Stem Cell-Derived Exosomes Inhibit Apoptosis in Ovarian Granulosa Cell via miR-369-3p/YAF2/PDCD5/p53 Pathway

Geng

Chen

Zou

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Human amniotic fluid stem cell-derived exosome (HuAFSC-exosome) transplantation is considered a promising treatment for premature ovarian failure (POF). However, its mechanism remains unclear. In this study, exosomes were isolated and enriched from HuAFSC subsets of CD44+/CD105+, and the exosomes were transplanted into a POF model in vitro and in vivo. Our results confirmed that the exosomes produced by CD44+/CD105+ HuAFSCs could achieve therapeutic effects in a mouse POF model. Our research also showed that CD44+/CD105+ HuAFSC-exosomes carrying miR-369-3p could specifically downregulate the expression of YAF2, inhibit the stability of PDCD5/p53, and reduce the apoptosis of ovarian granulosa cells (OGCs), thereby exerting therapeutic effects on POF. Knowledge of these mechanisms demonstrates that miRNAs carried by CD44+/CD105+ HuAFSC-exosomes are critical to the therapy of POF. This will be useful for the clinical application of stem cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Amniotic Fluid Mesenchymal Stem Cell-Derived Exosomes Inhibit Apoptosis in Ovarian Granulosa Cell via miR-369-3p/YAF2/PDCD5/p53 Pathway

Geng

Chen

Zou

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Anchoring drugs to the exosomal marker via a medium such as CP05 peptide-mediated CD63 linkage simplifies drug loading approaches ( 82 ). However, for cancer therapy, exosomes are mostly administered at doses of 100-600 μg exosomal proteins per mouse, which implies consumption of approximately 1 L cell supernatant, severely hindering the application of exosomes as drug vehicles ( 83 , 84 ). Cell membrane vesicles and exosomes share most of the characteristics of biomimetic nanovehicles, yet the former has superiority in terms of yield, production stability, and size homogeneity ( 11 , 12 ).…”

Section: Comparison Of Cellular Vesicles With Other Nanovehiclesmentioning

confidence: 99%

Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy

Zhang

2022

Front. Immunol.

View full text Add to dashboard Cite

As nano-sized materials prepared by isolating, disrupting and extruding cell membranes, cellular vesicles are emerging as a novel vehicle for immunotherapeutic drugs to activate antitumor immunity. Cell membrane-derived vesicles inherit the surface characteristics and functional properties of parental cells, thus having superior biocompatibility, low immunogenicity and long circulation. Moreover, the potent antitumor effect of cellular vesicles can be achieved through surface modification, genetic engineering, hybridization, drug encapsulation, and exogenous stimulation. The capacity of cellular vesicles to combine drugs of different compositions and functions in physical space provides a promising vehicle for combinational immunotherapy of cancer. In this review, the latest advances in cellular vesicles as vehicles for combinational cancer immunotherapy are systematically summarized with focuses on manufacturing processes, cell sources, therapeutic strategies and applications, providing an insight into the potential and existing challenges of using cellular vesicles for cancer immunotherapy.

show abstract

“…Ultracentrifugation requires fewer reagents and less operator expertise. Still, it may induce aggregates comprising various EVs and may be contaminated by lipoproteins with similar density [61,62].…”

Section: Ultracentrifugationmentioning

confidence: 99%

Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges

Zhang¹,

Li²,

Gao³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Exosomes, a subset of extracellular vesicles, are widely present in various body fluids and are involved in mediating intercellular communication. They have received extensive attention as diagnostic markers. The excellent physicochemical and biological properties of exosomes make them great potential drug delivery vehicles for the treatment of cancer and other diseases. However, various challenges need to be addressed for the clinical application of exosomes. This review introduces the biogenesis and uptake of exosomes and compares different approaches for isolation and drug loading, focusing on the application and current challenges of exosomes as drug delivery vehicles in cancer therapy.

show abstract

Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake

Cited by 178 publications

References 77 publications

Human Amniotic Fluid Mesenchymal Stem Cell-Derived Exosomes Inhibit Apoptosis in Ovarian Granulosa Cell via miR-369-3p/YAF2/PDCD5/p53 Pathway

Human Amniotic Fluid Mesenchymal Stem Cell-Derived Exosomes Inhibit Apoptosis in Ovarian Granulosa Cell via miR-369-3p/YAF2/PDCD5/p53 Pathway

Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy

Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges

Contact Info

Product

Resources

About